For our European readers who have not yet started, but are getting ready to start hormone deprivation therapy (ADT), there is a new clinical trial you should consider. This trial is evaluating MDV3100 monotherapy as the first hormonal treatment of patients with prostate cancer. Enrolled men would not have had any previous hormonal therapies for [...]
Over the last year or so we have seen a marked change in the treatment landscape for men with castrate resistant advanced prostate cancer. The FDA has approved sipuleucel-T (Provenge), cabazitaxel (Jevtana) and last week it also approved abiraterone (Zytiga). This changed landscape of multiple treatment options creates new problems, of course good problems. Prostate [...]
We often talk about the assumed fact that androgen deprivation therapy (ADT) changes both the blood glucose levels as well as cholesterol levels in men who are under treatment. Researchers at the Division of General Internal Medicine & Clinical Epidemiology, University Health Network, University of Toronto, Toronto, ON. decided to formally evaluate this theory over [...]
Another small confirmatory study of acupuncture to treat the side effects of hormone deprivation (ADT) was published in the International Journal of Radiation Oncology. The study found that acupuncture appears to provide long-lasting relief to hot flashes, heart palpitations, and anxiety due to side effects of hormone treatment for prostate cancer. […]
I recently made a video with Dr. James Mckiernan of Columbia Presbyterian Hospital in New York City on the use of Zometa (zoledronic acid) to combat bone metastases in advanced prostate cancer that is castrate resistant. Novartis Oncology, the makers of Zometa, sponsored the video and it was produced on the Wego Health web page. [...]